Skip to main content
. 2020 Aug 21;66(6):515–522. doi: 10.1262/jrd.2020-082

Fig. 7.

Fig. 7.

The number of BrdU-positive cells among purified CD9-positive cells treated with DES. (A) Merged images showing DAPI staining (blue), BrdU immunocytochemistry (green), and CD9 immunocytochemistry (red) 48 h after CD9-positive cells were cultured with non-silencing siRNAs (left) or Cd9- and Cd81-siRNAs (right), with or without DES (as indicated). Arrowheads indicate cells that were double-positive for CD9 and BrdU. Scale bar, 10 μm. (B) Proportion of BrdU-positive cells among CD9-positive cells (mean ± SEM, n = 3). ** P < 0.01.